Seres Therapeutics Sinks 74% After Lead Drug Fails in StudyBy
Results from phase 2 trial weren’t statistically significant
Drug had been granted breakthrough therapy status by FDA
Seres Therapeutics Inc. shares lost three quarters of their value Friday after the biotechnology company said its lead experimental drug failed in a clinical trial testing it against hard-to-treat intestinal infections.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.